Delivery Order SPE2DB24D1205-SPE2DB25FDALF
- Not listed
- The Defense Logistics Agency awarded a $279,751.97 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of SKYRIZI 150 MG/ML in pen/milliliter formulation. This is a firm fixed price contract with no set-aside designation, executed as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract is set to be completed by September 9, 2025, with fulfillment occurring at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of SKYRIZI 150 mg/ml pens with a ceiling value of $16,459.82. This firm fixed price delivery order, which completes on August 26, 2025, represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a $11,830.00 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML pen/milliliter pharmaceutical product on September 4, 2025, with completion expected by September 5, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $104,137.72 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen medication on August 14, 2025, with completion targeted for August 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a biologic immunosuppressant used to treat inflammatory skin conditions, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/mL in pen form, valued at $24,893.20 under a firm fixed-price contract awarded on August 24, 2025. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion master contract running through December 2026 that serves as a comprehensive global pharmaceutical...
- The Defense Logistics Agency awarded a $43,004.55 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of SKYRIZI 150 mg/ml pen vials. This is a non-set-aside, competitively awarded contract with an ultimate completion date of August 12, 2025, and performance at the contractor's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $46,515.57 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML pen/milliliter on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of SKYRIZI 150 MG/ML PenML, a pharmaceutical product, with a ceiling value of $26,166.64. This competitively awarded, firm fixed-price delivery order is set to conclude on August 19, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $113,263.44 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of SKYRIZI 150 mg/mL pen injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation, with performance to be completed by August 8, 2025, at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $94,011.78 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML PenML, a pharmaceutical product. This is a firm fixed price delivery order issued on September 8, 2025, with an ultimate completion date of September 9, 2025, and represents a non-competitive set-aside contract. The award will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate office and...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FDALFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of SKYRIZI 150 mg/ml in pen/ml formulation, with a ceiling value of $24,342.14. This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that supplies a comprehensive range of pharmaceutical products and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company was competitively selected for this delivery order, consistent with its track record of fulfilling federal medical supply needs through open competition. SKYRIZI is a dermatological biologic medication, and this order represents one of multiple pharmaceutical deliveries the contractor executes under its expansive DLA prime contract, which enables flexible support across multiple therapeutic domains and medical commodity categories for military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.3k | 9/12/25 |